Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Ridinilazole outperforms vancomycin in C. diff. trial
June 2017
SHARING OPTIONS:

OXFORD, U.K.—Drug discovery and development company Summit Therapeutics plc recently shared that results from its Phase 2 CoDIFy trial were published online in The Lancet Infectious Diseases. CoDIFy assessed ridinilazole, Summit’s novel antibiotic for the treatment of C. difficile infection (CDI), against vancomycin, the current standard of care. Ridinilazole showed substantial clinical benefit over vancomycin, including achieving statistical superiority in sustained clinical response, a composite endpoint of cure when treatment was complete and no recurrence 30 days after treatment.
 
“The results of our CoDIFy trial provided further evidence of ridinilazole’s ability to address the key clinical issue of recurrence, which could lead to improved patient care and reduced economic burden of CDI. We are therefore planning to progress this novel program into Phase 3 clinical trials. With ridinilazole, we believe we have a promising potential treatment option for this potentially fatal infectious disease,” said Glyn Edwards, Summit CEO.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.